[{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Neuraxpharm"}]

Find Clinical Drug Pipeline Developments & Deals for Levomepromazine Maleate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Levomepromazine Maleate

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Approved FDF

                          Sponsor : Neuraxpharm

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Details : The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal,...

                          Product Name : Nozinan

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 02, 2023

                          Lead Product(s) : Levomepromazine Maleate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Neuraxpharm

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Levomepromazine Maleate

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Approved FDF

                          Sponsor : Neuraxpharm

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Details : Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of se...

                          Product Name : Nozinan

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 07, 2022

                          Lead Product(s) : Levomepromazine Maleate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Neuraxpharm

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Sanofi Company Banner